Detection of hepatocellular carcinoma with PET/CT: A prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease

Journal of Nuclear Medicine

Volumn 51, Issue 11, 2010, Pages 1699-1706

  Talbot, Jean Noël ^a   Fartoux, Laetitia ^b   Balogova, Sona ^a,c   Nataf, Valérie ^a   Kerrou, Khaldoun ^a   Gutman, Fabrice ^a   Huchet, Virginie ^a   Ancel, David ^a   Grange, Jean Didier ^a   Rosmorduc, Olivier ^b  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

18F FDG PET CT; 18F fluorocholine PET CT; Hepatocellular carcinoma; Liver nodule; Prospective comparison

Indexed keywords

FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER STAGING; CHRONIC LIVER DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSENSUS; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER NODULE; LUNG METASTASIS; MAJOR CLINICAL STUDY; NODULAR HYPERPLASIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RECTUM CANCER; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; WHOLE BODY CT; WHOLE BODY PET;

BIOLOGICAL TRANSPORT; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CHOLINE; CHRONIC DISEASE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79851493457     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.075507     Document Type: Article

References (30)

1. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. (Pubitemid 32844200)
2. Bennett GL, Krinsky GA, Abitbol RJ, Kim SY, Theise ND, Teperman LW. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. AJR. 2002;179:75-80. (Pubitemid 34694814)
3. Snowberger N, Chinnakotla S, Lepe RM, et al Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther. 2007;26:1187-1194. (Pubitemid 47620421)
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699. (Pubitemid 26079803)
5. Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med. 2003;28:192-197. (Pubitemid 38281975)
6. 131Ilipiodol treatment for primary liver cancer. Cancer Biother Radiopharm. 2009;24:445-452.
7. Chen YK, Hsieh DS, Liao CS, et al. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res. 2005;25:4719-4725.
8. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr., Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133:510-515.
9. Verhoef C, Valkema R, de Man RA, Krenning EP, Yzermans JN. Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography. Liver. 2002;22:51-56. (Pubitemid 34552525)
10. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32:792-797. (Pubitemid 30262739)
11. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314-3319.
12. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36:1811-1817.
13. 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1467-1472.
14. 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol. 2010;45:560-566.
15. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using non invasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224:748-756.
16. 18F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging. 2008;35:1323-1329.
17. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44:213-221.
18. Kuo YT, Li CW, Chen CY, Jao J, Wu DK, Liu GC. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging. 2004;19:598-604.
19. Gharib AM, Thomasson D, Li KC. Molecular imaging of hepatocellular carcinoma. Gastroenterology. 2004;127(5, suppl 1):S153-S158. (Pubitemid 39423383)
20. Talbot JN, Gutman F, Fartoux L, et al. PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006;33:1285-1289. (Pubitemid 44630783)
21. Strobel D, Seitz K, Blank W, et al. Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1,349 liver lesions in contrast-enhanced ultrasound (CEUS). Ultraschall Med. 2009;30:376-382.
22. 18F-FDG PET. J Nucl Med. 2008;49:1245-1248.
23. Lenzo NP, Anderson J, Campbell A, et al. Fluoromethylcholine PET in recurrent multifocal hepatoma. Australas Radiol. December 2007;(51, suppl):B299-B302.
24. 18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg. 2003;69:117-124.
25. 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912-1921.
26. Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med. 2007;48:902-909. (Pubitemid 46909918)
27. Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. 2007;37:420-428. (Pubitemid 47498259)
28. Kurtaran A, Becherer A, Pfeffel F, et al. 18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver. Liver. 2000;20:487-490. (Pubitemid 32000742)
29. Aznar DL, Ojeda R, Garcia EU, et al. Focal nodular hyperplasia (FNH): a potential cause of false-positive positron emission tomography. Clin Nucl Med. 2005;30:636-637. (Pubitemid 41216164)
30. Magini G, Farsad M, Frigerio M, et al. C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. Clin Nucl Med. 2009;34:659-665.